vs
PHIBRO ANIMAL HEALTH CORP（PAHC）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
PHIBRO ANIMAL HEALTH CORPの直近四半期売上が大きい（$373.9M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.3倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 7.3%、差は9.1%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $8.3M）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs 1.2%）
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
PAHC vs PBH — 直接比較
損益計算書 — Q2 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $373.9M | $283.4M |
| 純利益 | $27.5M | $46.7M |
| 粗利率 | 35.5% | 55.5% |
| 営業利益率 | 13.5% | 29.1% |
| 純利益率 | 7.3% | 16.5% |
| 売上前年比 | 20.9% | -2.4% |
| 純利益前年比 | 762.1% | -23.5% |
| EPS（希薄化後） | $0.67 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $373.9M | $283.4M | ||
| Q3 25 | $363.9M | $274.1M | ||
| Q2 25 | $378.7M | $249.5M | ||
| Q1 25 | $347.8M | $296.5M | ||
| Q4 24 | $309.3M | $290.3M | ||
| Q3 24 | $260.4M | $283.8M | ||
| Q2 24 | $273.2M | $267.1M | ||
| Q1 24 | $263.2M | $277.0M |
| Q4 25 | $27.5M | $46.7M | ||
| Q3 25 | $26.5M | $42.2M | ||
| Q2 25 | $17.2M | $47.5M | ||
| Q1 25 | $20.9M | $50.1M | ||
| Q4 24 | $3.2M | $61.0M | ||
| Q3 24 | $7.0M | $54.4M | ||
| Q2 24 | $752.0K | $49.1M | ||
| Q1 24 | $8.4M | $49.5M |
| Q4 25 | 35.5% | 55.5% | ||
| Q3 25 | 32.9% | 55.3% | ||
| Q2 25 | 29.0% | 56.2% | ||
| Q1 25 | 30.1% | 57.3% | ||
| Q4 24 | 32.9% | 55.5% | ||
| Q3 24 | 32.1% | 55.5% | ||
| Q2 24 | 31.9% | 54.7% | ||
| Q1 24 | 30.2% | 54.8% |
| Q4 25 | 13.5% | 29.1% | ||
| Q3 25 | 14.1% | 29.1% | ||
| Q2 25 | 8.9% | 28.8% | ||
| Q1 25 | 9.6% | 29.8% | ||
| Q4 24 | 8.3% | 31.7% | ||
| Q3 24 | 6.8% | 29.7% | ||
| Q2 24 | 6.7% | 27.0% | ||
| Q1 24 | 7.6% | 29.7% |
| Q4 25 | 7.3% | 16.5% | ||
| Q3 25 | 7.3% | 15.4% | ||
| Q2 25 | 4.5% | 19.0% | ||
| Q1 25 | 6.0% | 16.9% | ||
| Q4 24 | 1.0% | 21.0% | ||
| Q3 24 | 2.7% | 19.2% | ||
| Q2 24 | 0.3% | 18.4% | ||
| Q1 24 | 3.2% | 17.9% |
| Q4 25 | $0.67 | $0.97 | ||
| Q3 25 | $0.65 | $0.86 | ||
| Q2 25 | $0.43 | $0.95 | ||
| Q1 25 | $0.51 | $1.00 | ||
| Q4 24 | $0.08 | $1.22 | ||
| Q3 24 | $0.17 | $1.09 | ||
| Q2 24 | $0.02 | $0.98 | ||
| Q1 24 | $0.21 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $74.5M | $62.4M |
| 総負債低いほど良い | $624.2M | $1.0B |
| 株主資本純資産 | $332.4M | $1.8B |
| 総資産 | $1.4B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 1.88× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $74.5M | $62.4M | ||
| Q3 25 | $85.3M | $119.1M | ||
| Q2 25 | $77.0M | $139.5M | ||
| Q1 25 | $70.4M | $97.9M | ||
| Q4 24 | $67.1M | $50.9M | ||
| Q3 24 | $89.8M | $51.5M | ||
| Q2 24 | $114.6M | $34.3M | ||
| Q1 24 | $98.7M | $46.5M |
| Q4 25 | $624.2M | $1.0B | ||
| Q3 25 | $628.0M | $993.1M | ||
| Q2 25 | $631.7M | $992.7M | ||
| Q1 25 | $635.4M | $992.4M | ||
| Q4 24 | $639.1M | $992.0M | ||
| Q3 24 | $295.2M | $1.1B | ||
| Q2 24 | $312.1M | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $332.4M | $1.8B | ||
| Q3 25 | $311.7M | $1.8B | ||
| Q2 25 | $285.7M | $1.9B | ||
| Q1 25 | $266.0M | $1.8B | ||
| Q4 24 | $246.8M | $1.8B | ||
| Q3 24 | $258.5M | $1.7B | ||
| Q2 24 | $256.6M | $1.7B | ||
| Q1 24 | $270.1M | $1.7B |
| Q4 25 | $1.4B | $3.5B | ||
| Q3 25 | $1.4B | $3.4B | ||
| Q2 25 | $1.4B | $3.4B | ||
| Q1 25 | $1.3B | $3.4B | ||
| Q4 24 | $1.3B | $3.3B | ||
| Q3 24 | $966.3M | $3.3B | ||
| Q2 24 | $982.2M | $3.3B | ||
| Q1 24 | $979.0M | $3.3B |
| Q4 25 | 1.88× | 0.56× | ||
| Q3 25 | 2.01× | 0.54× | ||
| Q2 25 | 2.21× | 0.54× | ||
| Q1 25 | 2.39× | 0.54× | ||
| Q4 24 | 2.59× | 0.55× | ||
| Q3 24 | 1.14× | 0.61× | ||
| Q2 24 | 1.22× | 0.65× | ||
| Q1 24 | — | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.4M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.3M | $75.3M |
| FCFマージンFCF / 売上 | 2.2% | 26.6% |
| 設備投資強度設備投資 / 売上 | 3.0% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 0.70× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $47.3M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.4M | $78.3M | ||
| Q3 25 | $9.3M | $57.5M | ||
| Q2 25 | $21.3M | $79.0M | ||
| Q1 25 | $43.2M | $61.8M | ||
| Q4 24 | $3.1M | $65.1M | ||
| Q3 24 | $12.6M | $69.8M | ||
| Q2 24 | $28.4M | $54.8M | ||
| Q1 24 | $11.4M | $66.9M |
| Q4 25 | $8.3M | $75.3M | ||
| Q3 25 | $-4.5M | $55.4M | ||
| Q2 25 | $8.1M | $78.2M | ||
| Q1 25 | $35.4M | $58.4M | ||
| Q4 24 | $-4.7M | $63.5M | ||
| Q3 24 | $3.0M | $67.8M | ||
| Q2 24 | $15.4M | $53.6M | ||
| Q1 24 | $1.7M | $63.8M |
| Q4 25 | 2.2% | 26.6% | ||
| Q3 25 | -1.2% | 20.2% | ||
| Q2 25 | 2.1% | 31.3% | ||
| Q1 25 | 10.2% | 19.7% | ||
| Q4 24 | -1.5% | 21.9% | ||
| Q3 24 | 1.2% | 23.9% | ||
| Q2 24 | 5.6% | 20.1% | ||
| Q1 24 | 0.6% | 23.0% |
| Q4 25 | 3.0% | 1.1% | ||
| Q3 25 | 3.8% | 0.8% | ||
| Q2 25 | 3.5% | 0.3% | ||
| Q1 25 | 2.2% | 1.2% | ||
| Q4 24 | 2.5% | 0.5% | ||
| Q3 24 | 3.7% | 0.7% | ||
| Q2 24 | 4.8% | 0.4% | ||
| Q1 24 | 3.7% | 1.1% |
| Q4 25 | 0.70× | 1.68× | ||
| Q3 25 | 0.35× | 1.36× | ||
| Q2 25 | 1.24× | 1.66× | ||
| Q1 25 | 2.07× | 1.23× | ||
| Q4 24 | 0.97× | 1.07× | ||
| Q3 24 | 1.81× | 1.28× | ||
| Q2 24 | 37.80× | 1.12× | ||
| Q1 24 | 1.36× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
